Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Sell
43
PRPO Quote, Financials, Valuation and Earnings
Last price:
$6.45
Seasonality move
:
2.93%
Day range:
$6.00 - $6.50
52-week range:
$3.90 - $10.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.51x
P/B ratio:
0.81x
Volume:
2.6K
Avg. volume:
14.6K
1-year change:
14.44%
Market cap:
$9.8M
Revenue:
$18.5M
EPS (TTM):
-$1.83
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Precipio has 192.31% upside to fair value with a price target of -- per share.
PRPO vs. S&P 500
-
Over the past 5 trading days, Precipio has overperformed the S&P 500 by 7.9% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Precipio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Precipio has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Precipio reported revenues of $5.2M.
Earnings Growth
-
Precipio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Precipio reported earnings per share of -$0.42.
Enterprise value:
8.8M
EV / Invested capital:
--
Price / LTM sales:
0.51x
EV / EBIT:
--
EV / Revenue:
0.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
40.57x
Price / Operating cash flow:
44.10x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$6.9M
Return On Assets:
-17.04%
Net Income Margin (TTM):
-17.23%
Return On Equity:
-23.34%
Return On Invested Capital:
-22.67%
Operating Margin:
-11.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $9.4M | $15.2M | $18.5M | $4.3M | $5.5M | |
| Gross Profit | $2.5M | $6M | $7.6M | $2M | $2.6M | |
| Operating Income | -$12.8M | -$7.6M | -$4.2M | -$854K | -$336K | |
| EBITDA | -$10.9M | -$4.3M | -$2.7M | $1.3M | $46K | |
| Diluted EPS | -$10.60 | -$4.65 | -$2.95 | $0.88 | -$0.24 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.2M | $13.5M | $5.7M | $3.7M | $3.5M | |
| Total Assets | $20.7M | $30.4M | $21.5M | $18.1M | $17M | |
| Current Liabilities | $4.7M | $4.2M | $4.4M | $3.1M | $4.3M | |
| Total Liabilities | $6.6M | $5.8M | $5.1M | $3.7M | $4.9M | |
| Total Equity | $14.2M | $24.6M | $16.4M | $14.4M | $12.1M | |
| Total Debt | $1M | $186K | $389K | $341K | $374K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.7M | -$3.6M | $439K | $114K | $565K | |
| Cash From Investing | -$277K | -$126K | -$223K | -$49K | -$44K | |
| Cash From Financing | -$225K | $1.7M | -$329K | -$125K | -$185K | |
| Free Cash Flow | -$8M | -$3.7M | $216K | $65K | $521K | |
PRPO
Sector
Market Cap
$9.8M
$34.5M
Price % of 52-Week High
60.51%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
-1.55%
-0.79%
1-Year Price Total Return
14.44%
-42.08%
Beta (5-Year)
1.118
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.32
200-day SMA
Buy
Level
$6.30
Bollinger Bands (100)
Buy
Level
5.52 - 7.4
Chaikin Money Flow
Buy
Level
2.1M
20-day SMA
Buy
Level
$6.05
Relative Strength Index (RSI14)
Buy
Level
52.33
ADX Line
Buy
Level
28.24
Williams %R
Neutral
Level
-69.0647
50-day SMA
Buy
Level
$6.40
MACD (12, 26)
Buy
Level
0.07
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
43.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.2116)
Buy
CA Score
(Annual)
Level (0.0407)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (3.0144)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Stock Forecast FAQ
In the current month, PRPO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PRPO average analyst price target in the past 3 months is --.
-
Where Will Precipio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Precipio share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Precipio?
Analysts are divided on their view about Precipio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Precipio is a Sell and believe this share price will drop from its current level to --.
-
What Is Precipio's Price Target?
The price target for Precipio over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PRPO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Precipio is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PRPO?
You can purchase shares of Precipio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Precipio shares.
-
What Is The Precipio Share Price Today?
Precipio was last trading at $6.45 per share. This represents the most recent stock quote for Precipio. Yesterday, Precipio closed at $6.50 per share.
-
How To Buy Precipio Stock Online?
In order to purchase Precipio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
